Literature DB >> 19941432

Mitigation of pandemic influenza: review of cost-effectiveness studies.

Anna K Lugnér1, Maarten J Postma.   

Abstract

We conducted a review of economic evaluations of pandemic influenza control measures. In the studies found, we detected various interventions being investigated: antiviral stockpiling and treatment, prophylaxis, vaccination, school closure and restricting international travel. Cost-effectiveness varied but often showed potentials for the favorable economic profiles of these measures. Both static and dynamic models were used. We conclude that the choice of an appropriate model - in particular, a dynamic model - is crucial to arrive at valid cost-effectiveness ratios. Yet, of the economic evaluations considered here, only a few were based on dynamic modeling. We recommend that further research is directed toward linking dynamic epidemiological models for pandemic spread with economic outcomes by considering the full impacts on national economies, including direct, indirect, medical and nonmedical costs.

Mesh:

Substances:

Year:  2009        PMID: 19941432     DOI: 10.1586/erp.09.56

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  10 in total

1.  Cost-effectiveness analysis of pandemic influenza preparedness: what's missing?

Authors:  Tom L Drake; Zaid Chalabi; Richard Coker
Journal:  Bull World Health Organ       Date:  2012-10-10       Impact factor: 9.408

2.  Lockdowned: Everyday mobility changes in response to COVID-19.

Authors:  Przemysław Borkowski; Magdalena Jażdżewska-Gutta; Agnieszka Szmelter-Jarosz
Journal:  J Transp Geogr       Date:  2020-11-11

3.  Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.

Authors:  T Déirdre Hollingsworth; Don Klinkenberg; Hans Heesterbeek; Roy M Anderson
Journal:  PLoS Comput Biol       Date:  2011-02-10       Impact factor: 4.475

Review 4.  Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics.

Authors:  Román Pérez Velasco; Naiyana Praditsitthikorn; Kamonthip Wichmann; Adun Mohara; Surachai Kotirum; Sripen Tantivess; Constanza Vallenas; Hande Harmanci; Yot Teerawattananon
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

5.  Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.

Authors:  D B C Wu; N Chaiyakunapruk; C Pratoomsoot; K K C Lee; H Y Chong; R E Nelson; P F Smith; C M Kirkpatrick; M A Kamal; K Nieforth; G Dall; S Toovey; D C M Kong; A Kamauu; C R Rayner
Journal:  Epidemiol Infect       Date:  2018-02-15       Impact factor: 4.434

Review 6.  Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Authors:  James R Smith; Craig R Rayner; Barbara Donner; Martina Wollenhaupt; Klaus Klumpp; Regina Dutkowski
Journal:  Adv Ther       Date:  2011-11-01       Impact factor: 3.845

7.  Cost-effectiveness of emergency preparedness measures in response to infectious respiratory disease outbreaks: a systematic review and econometric analysis.

Authors:  Constantine Vardavas; Katerina Nikitara; Konstantinos Zisis; Konstantinos Athanasakis; Revati Phalkey; Jo Leonardi-Bee; Helen Johnson; Svetla Tsolova; Massimo Ciotti; Jonathan E Suk
Journal:  BMJ Open       Date:  2021-04-29       Impact factor: 2.692

8.  Identifying the relative priorities of subpopulations for containing infectious disease spread.

Authors:  Shang Xia; Jiming Liu; William Cheung
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

9.  Investigating duration and intensity of Covid-19 social-distancing strategies.

Authors:  C Neuwirth; C Gruber; T Murphy
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.379

10.  Buy now, saved later? The critical impact of time-to-pandemic uncertainty on pandemic cost-effectiveness analyses.

Authors:  Tom Drake; Zaid Chalabi; Richard Coker
Journal:  Health Policy Plan       Date:  2013-12-24       Impact factor: 3.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.